You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevodopa
Accession NumberDB01235  (APRD00309, EXPT01107)
TypeSmall Molecule
GroupsApproved
DescriptionThe naturally occurring form of dihydroxyphenylalanine and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonian disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. [PubChem]
Structure
Thumb
Synonyms
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-Dopa
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
3-Hydroxy-L-tyrosine
3,4-Dihydroxy-L-phenylalanine
3,4-DIHYDROXYPHENYLALANINE
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)alanine
Dihydroxy-L-phenylalanine
Dopar
L-3,4-dihydroxyphenylalanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-DOPA
Levodopa
Levodopum
β-(3,4-dihydroxyphenyl)alanine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carbidopa and LevodopaTablet25 mg/1OralREMEDYREPACK INC.2013-02-272016-10-18Us
Carbidopa and LevodopaTablet25 mg/1OralREMEDYREPACK INC.2013-03-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BidopalGlaxoSmithKline
DoparNot Available
DoparlKyowa Hakko Kirin
DopasolDaiichi Sankyo
DopastonOhara Yakuhin
Brand mixtures
NameLabellerIngredients
Apo-levocarb - Tab 10mg/100mgApotex Inc
Apo-levocarb - Tab 25mg/250mgApotex Inc
Apo-levocarb CRApotex Inc
Apo-levocarb-tab 25mg/100mgApotex Inc
Carbidopa and LevodopaTeva Pharmaceuticals USA Inc
Carbidopa, Levodopa and EntacaponeSun Pharma Global FZE
Carbidopa, Levodopa, and EntacaponeSandoz Inc
Dom-levo-carbidopaDominion Pharmacal
DuodopaAbbvie Corporation
DuopaAbb Vie Inc.
Mint-levocarbMint Pharmaceuticals Inc
Nu-levocarb - Tab 10mg/100mgNu Pharm Inc
Nu-levocarb - Tab 25 Mg/100 mgNu Pharm Inc
Nu-levocarb - Tablets 25 Mg/250 mgNu Pharm Inc
NumientImpax Laboratories (Netherlands) Bv
ParcopaJazz Pharmaceuticals, Inc.
PMS-levocarb CRPharmascience Inc
Pro-lecarb-100/10 - TabPro Doc Limitee
Pro-lecarb-100/25 - TabPro Doc Limitee
Pro-levocarb - 100/25Pro Doc Limitee
Prolopa Cap 100-25Hoffmann La Roche Limited
Prolopa Cap 200-50Hoffmann La Roche Limited
Prolopa Cap 50-12.5Hoffmann La Roche Limited
Ratio-levodopa/carbidopaRatiopharm Inc Division Of Teva Canada Limited
RytaryImpax Specialty Pharma
SinemetMerck Sharp & Dohme Corp.
Sinemet 100/10Merck Canada Inc
Sinemet 100/25Merck Canada Inc
Sinemet 250/25Merck Canada Inc
Sinemet CRMerck Sharp & Dohme Corp.
Sinemet CR 100/25Merck Canada Inc
Sinemet CR 200/50Merck Canada Inc
StalevoNovartis Pharmaceuticals Canada Inc
Teva-levocarbidopaTeva Canada Limited
SaltsNot Available
Categories
UNII46627O600J
CAS number59-92-7
WeightAverage: 197.1879
Monoisotopic: 197.068807845
Chemical FormulaC9H11NO4
InChI KeyWTDRDQBEARUVNC-LURJTMIESA-N
InChI
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
IUPAC Name
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
SMILES
N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
Pharmacology
IndicationFor the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication.
Structured Indications
PharmacodynamicsLevodopa (L-dopa) is used to replace dopamine lost in Parkinson's disease because dopamine itself cannot cross the blood-brain barrier where its precursor can. However, L-DOPA is converted to dopamine in the periphery as well as in the CNS, so it is administered with a peripheral DDC (dopamine decarboxylase) inhibitor such as carbidopa, without which 90% is metabolised in the gut wall, and with a COMT inhibitor if possible; this prevents about a 5% loss. The form given therapeutically is therefore a prodrug which avoids decarboxylation in the stomach and periphery, can cross the blood-brain barrier, and once in the brain is converted to the neurotransmitter dopamine by the enzyme aromatic-L-amino-acid decarboxylase.
Mechanism of actionStriatal dopamine levels in symptomatic Parkinson's disease are decreased by 60 to 80%, striatal dopaminergic neurotransmission may be enhanced by exogenous supplementation of dopamine through administration of dopamine's precursor, levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier and is decarboxylated to dopamine. This newly formed dopamine then is available to stimulate dopaminergic receptors, thus compensating for the depleted supply of endogenous dopamine.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(1A) dopamine receptorProteinyes
agonist
HumanP21728 details
D(1B) dopamine receptorProteinyes
agonist
HumanP21918 details
D(2) dopamine receptorProteinyes
agonist
HumanP14416 details
D(3) dopamine receptorProteinyes
agonist
HumanP35462 details
D(4) dopamine receptorProteinyes
agonist
HumanP21917 details
Related Articles
AbsorptionLevodopa is rapidly absorbed from the proximal small intestine by the large neutral amino acid (LNAA) transport carrier system.
Volume of distributionNot Available
Protein bindingHigh
Metabolism

95% of an administered oral dose of levodopa is pre-systemically decarboxylated to dopamine by the L-aromatic amino acid decarboxylase (AAAD) enzyme in the stomach, lumen of the intestine, kidney, and liver. Levodopa also may be methoxylated by the hepatic catechol-O-methyltransferase (COMT) enzyme system to 3-O-methyldopa (3-OMD), which cannot be converted to central dopamine.

SubstrateEnzymesProduct
Levodopa
Not Available
DOPA sulfateDetails
Route of eliminationNot Available
Half life50 to 90 minutes
ClearanceNot Available
ToxicityOral, mouse: LD50 = 2363 mg/kg; Oral, rabbit: LD50 = 609 mg/kg; Oral, rat: LD50 = 1780 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Aromatic L-Aminoacid Decarboxylase DeficiencyDiseaseSMP00170
Catecholamine BiosynthesisMetabolicSMP00012
Tyrosinemia Type IDiseaseSMP00218
Disulfiram Action PathwayDrug actionSMP00429
Tyrosine hydroxylase deficiencyDiseaseSMP00497
Tyrosine MetabolismMetabolicSMP00006
Tyrosinemia, transient, of the newbornDiseaseSMP00494
AlkaptonuriaDiseaseSMP00169
HawkinsinuriaDiseaseSMP00190
Dopamine beta-hydroxylase deficiencyDiseaseSMP00498
Monoamine oxidase-a deficiency (MAO-A)DiseaseSMP00533
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Levodopa is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levodopa.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Levodopa is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Levodopa can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Levodopa.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Levodopa.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levodopa.Approved
AcetazolamideAcetazolamide may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Levodopa.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levodopa.Approved, Investigational
AldesleukinAldesleukin may increase the orthostatic hypotensive activities of Levodopa.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levodopa.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levodopa.Approved, Illicit
AliskirenAliskiren may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Levodopa.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levodopa.Approved, Illicit, Investigational
AmifostineAmifostine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
AmilorideAmiloride may increase the orthostatic hypotensive activities of Levodopa.Approved
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Levodopa.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levodopa.Approved
AmlodipineAmlodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levodopa.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levodopa.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Levodopa.Experimental
Amphotericin BAmphotericin B may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
Amyl NitriteAmyl Nitrite may increase the orthostatic hypotensive activities of Levodopa.Approved
ApomorphineApomorphine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
ApraclonidineApraclonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Levodopa.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Levodopa.Approved
Arsenic trioxideArsenic trioxide may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
ArtemetherThe metabolism of Levodopa can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Levodopa.Approved
AsenapineThe therapeutic efficacy of Levodopa can be decreased when used in combination with Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Levodopa.Approved
AtomoxetineThe metabolism of Levodopa can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Levodopa.Vet Approved
AzelastineLevodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levodopa.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the orthostatic hypotensive activities of Levodopa.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Levodopa.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Levodopa.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Levodopa.Illicit
BarnidipineBarnidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
BenazeprilBenazepril may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Levodopa is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Levodopa is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Levodopa.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levodopa.Approved
BepridilBepridil may increase the orthostatic hypotensive activities of Levodopa.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Levodopa.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Levodopa.Approved
BlonanserinThe therapeutic efficacy of Levodopa can be decreased when used in combination with Blonanserin.Approved
BortezomibBortezomib may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
BretyliumBretylium may increase the orthostatic hypotensive activities of Levodopa.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levodopa is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levodopa.Approved, Illicit
BromocriptineBromocriptine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levodopa.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Levodopa.Approved, Withdrawn
BumetanideBumetanide may increase the orthostatic hypotensive activities of Levodopa.Approved
BupivacaineBupivacaine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
BuprenorphineLevodopa may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Levodopa is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levodopa.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levodopa.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Levodopa.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Levodopa.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Levodopa.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Levodopa.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levodopa.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
CandesartanCandesartan may increase the orthostatic hypotensive activities of Levodopa.Approved
CaptoprilCaptopril may increase the orthostatic hypotensive activities of Levodopa.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levodopa.Approved, Investigational
CarbetocinCarbetocin may increase the orthostatic hypotensive activities of Levodopa.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levodopa.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Levodopa.Illicit, Vet Approved
CariprazineThe therapeutic efficacy of Levodopa can be decreased when used in combination with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levodopa.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Levodopa is combined with Caroxazone.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Levodopa.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
CelecoxibThe metabolism of Levodopa can be decreased when combined with Celecoxib.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levodopa.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levodopa.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levodopa.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Levodopa.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levodopa.Approved
ChloroquineThe metabolism of Levodopa can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levodopa.Approved
ChlorpromazineChlorpromazine may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
ChlorprothixeneThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Levodopa.Approved, Withdrawn
ChlorthalidoneChlorthalidone may increase the orthostatic hypotensive activities of Levodopa.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levodopa.Approved
CholecalciferolThe metabolism of Levodopa can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilCilazapril may increase the orthostatic hypotensive activities of Levodopa.Approved
CilnidipineCilnidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
CimetidineThe metabolism of Levodopa can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Levodopa can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levodopa.Approved, Vet Approved
CitalopramThe metabolism of Levodopa can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Levodopa can be decreased when combined with Clemastine.Approved
ClevidipineClevidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Levodopa.Approved
ClobazamThe metabolism of Levodopa can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineClofarabine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Levodopa.Investigational
ClomipramineClomipramine may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levodopa.Approved, Illicit
ClonidineClonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levodopa.Approved, Illicit
ClotrimazoleThe metabolism of Levodopa can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the orthostatic hypotensive activities of Levodopa.Approved
CobicistatThe serum concentration of Levodopa can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Levodopa can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levodopa.Approved, Illicit
ConivaptanConivaptan may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levodopa.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levodopa.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levodopa.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levodopa.Approved
DapagliflozinDapagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levodopa.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Levodopa is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Levodopa can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Levodopa can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Levodopa can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Levodopa.Investigational
DesfluraneDesflurane may increase the orthostatic hypotensive activities of Levodopa.Approved
DesipramineThe metabolism of Levodopa can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levodopa.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Levodopa is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Levodopa.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa.Approved
DexmedetomidineDexmedetomidine may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Levodopa.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levodopa.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Levodopa.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levodopa.Approved, Illicit, Vet Approved
DiclofenamideDiclofenamide may increase the orthostatic hypotensive activities of Levodopa.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Levodopa is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levodopa.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levodopa.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levodopa.Experimental, Illicit
DiltiazemDiltiazem may increase the orthostatic hypotensive activities of Levodopa.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levodopa.Approved
DinutuximabDinutuximab may increase the orthostatic hypotensive activities of Levodopa.Approved
DiphenhydramineThe metabolism of Levodopa can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levodopa.Approved, Illicit
DipyridamoleDipyridamole may increase the orthostatic hypotensive activities of Levodopa.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Levodopa.Vet Approved
DoxazosinDoxazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Levodopa.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Levodopa.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved, Illicit
DronedaroneThe metabolism of Levodopa can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Levodopa.Experimental, Illicit
DuloxetineLevodopa may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levodopa.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Levodopa.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Levodopa.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Levodopa is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levodopa.Approved, Investigational
EfonidipineEfonidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
EliglustatThe metabolism of Levodopa can be decreased when combined with Eliglustat.Approved
EmpagliflozinEmpagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
EnalaprilEnalapril may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the orthostatic hypotensive activities of Levodopa.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levodopa.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Levodopa.Approved, Investigational
EplerenoneEplerenone may increase the orthostatic hypotensive activities of Levodopa.Approved
EpoprostenolEpoprostenol may increase the orthostatic hypotensive activities of Levodopa.Approved
EprosartanEprosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Levodopa is combined with Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Levodopa.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levodopa.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levodopa.Approved
Etacrynic acidEtacrynic acid may increase the orthostatic hypotensive activities of Levodopa.Approved
EthanolLevodopa may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levodopa.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levodopa.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levodopa.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levodopa.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levodopa.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levodopa.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Levodopa.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Levodopa.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Levodopa.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levodopa.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Levodopa is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Levodopa.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Levodopa is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Levodopa.Approved
FelodipineFelodipine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levodopa.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the orthostatic hypotensive activities of Levodopa.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levodopa.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseThe serum concentration of Levodopa can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Levodopa can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Levodopa can be decreased when it is combined with Ferric pyrophosphate.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levodopa.Approved
FimasartanFimasartan may increase the orthostatic hypotensive activities of Levodopa.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Levodopa is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levodopa.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Levodopa is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levodopa.Approved, Illicit
FluoxetineThe metabolism of Levodopa can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Levodopa.Approved, Withdrawn
FluphenazineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Levodopa.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levodopa.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levodopa.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levodopa.Approved
FluvoxamineThe metabolism of Levodopa can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilFosinopril may increase the orthostatic hypotensive activities of Levodopa.Approved
FosphenytoinThe therapeutic efficacy of Levodopa can be decreased when used in combination with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levodopa.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Levodopa is combined with Furazolidone.Approved, Vet Approved
FurosemideFurosemide may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levodopa.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Levodopa is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levodopa.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Levodopa is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Levodopa.Approved, Illicit
GlycopyrroniumThe serum concentration of Levodopa can be decreased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineGuanfacine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levodopa.Approved, Illicit, Withdrawn
HaloperidolThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Levodopa.Approved
HalothaneHalothane may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Levodopa.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levodopa.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Hydracarbazine.Approved
HydralazineHydralazine may increase the orthostatic hypotensive activities of Levodopa.Approved
HydrochlorothiazideHydrochlorothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
HydrocodoneLevodopa may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levodopa.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
IloperidoneThe therapeutic efficacy of Levodopa can be decreased when used in combination with Iloperidone.Approved
IloprostIloprost may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
ImidaprilImidapril may increase the orthostatic hypotensive activities of Levodopa.Investigational
ImipramineImipramine may increase the orthostatic hypotensive activities of Levodopa.Approved
IndalpineThe risk or severity of adverse effects can be increased when Levodopa is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the orthostatic hypotensive activities of Levodopa.Approved
IndinavirThe metabolism of Levodopa can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the orthostatic hypotensive activities of Levodopa.Withdrawn
IproclozideThe risk or severity of adverse effects can be increased when Levodopa is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Levodopa is combined with Iproniazid.Withdrawn
IrbesartanIrbesartan may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
IronThe serum concentration of Levodopa can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Levodopa can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Levodopa can be decreased when it is combined with Iron saccharate.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Levodopa is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
IsoniazidThe therapeutic efficacy of Levodopa can be decreased when used in combination with Isoniazid.Approved
Isosorbide DinitrateIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Levodopa.Approved
Isosorbide MononitrateIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Levodopa.Approved
IsoxsuprineIsoxsuprine may increase the orthostatic hypotensive activities of Levodopa.Approved, Withdrawn
IsradipineIsradipine may increase the orthostatic hypotensive activities of Levodopa.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levodopa.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levodopa.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levodopa.Approved
KetoconazoleThe metabolism of Levodopa can be decreased when combined with Ketoconazole.Approved, Investigational
L-MethionineThe therapeutic efficacy of Levodopa can be decreased when used in combination with L-Methionine.Approved, Nutraceutical
LabetalolLabetalol may increase the orthostatic hypotensive activities of Levodopa.Approved
LacidipineLacidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levodopa.Approved, Investigational
LercanidipineLercanidipine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levodopa.Approved, Investigational
LevobunololLevobunolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevobupivacaineLevobupivacaine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levodopa is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levodopa is combined with Levocetirizine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levodopa.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levodopa is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levodopa.Approved
LevosimendanLevosimendan may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levodopa.Approved, Vet Approved
LisinoprilLisinopril may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Levodopa.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Levodopa.Illicit
LofexidineLofexidine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
LopinavirThe metabolism of Levodopa can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Levodopa.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levodopa.Approved
LorcaserinThe metabolism of Levodopa can be decreased when combined with Lorcaserin.Approved
LosartanLosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LoxapineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Levodopa.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Levodopa.Investigational
LumateperoneThe therapeutic efficacy of Levodopa can be decreased when used in combination with Lumateperone.Investigational
LumefantrineThe metabolism of Levodopa can be decreased when combined with Lumefantrine.Approved
LurasidoneThe therapeutic efficacy of Levodopa can be decreased when used in combination with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved, Vet Approved
MannitolMannitol may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levodopa.Approved
MebanazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Mebanazine.Withdrawn
MecamylamineMecamylamine may increase the orthostatic hypotensive activities of Levodopa.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levodopa.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Levodopa.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Levodopa.Approved, Nutraceutical, Vet Approved
MelperoneThe therapeutic efficacy of Levodopa can be decreased when used in combination with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levodopa.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levodopa.Approved, Illicit
MesoridazineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Levodopa.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levodopa.Approved
MethadoneThe metabolism of Levodopa can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Levodopa.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levodopa.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levodopa.Illicit, Withdrawn
MethazolamideMethazolamide may increase the orthostatic hypotensive activities of Levodopa.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levodopa.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levodopa.Approved
MethotrimeprazineLevodopa may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levodopa.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Levodopa is combined with Methsuximide.Approved
MethyclothiazideMethyclothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
MethyldopaMethyldopa may increase the orthostatic hypotensive activities of Levodopa.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Levodopa is combined with Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Levodopa.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levodopa.Approved
MetipranololMetipranolol may increase the orthostatic hypotensive activities of Levodopa.Approved
MetoclopramideThe therapeutic efficacy of Levodopa can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneMetolazone may increase the orthostatic hypotensive activities of Levodopa.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
MetyrosineLevodopa may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levodopa.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Levodopa is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Levodopa is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved, Investigational
MinoxidilMinoxidil may increase the orthostatic hypotensive activities of Levodopa.Approved
MirabegronThe metabolism of Levodopa can be decreased when combined with Mirabegron.Approved
MirtazapineLevodopa may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Levodopa is combined with Moclobemide.Approved
MoexiprilMoexipril may increase the orthostatic hypotensive activities of Levodopa.Approved
MolindoneThe therapeutic efficacy of Molindone can be decreased when used in combination with Levodopa.Approved
MorphineMorphine may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
MoxonidineMoxonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Levodopa.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levodopa.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Levodopa is combined with Nefazodone.Approved, Withdrawn
NesiritideNesiritide may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
NevirapineThe metabolism of Levodopa can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Levodopa is combined with Nialamide.Withdrawn
NicardipineNicardipine may increase the orthostatic hypotensive activities of Levodopa.Approved
NicorandilNicorandil may increase the hypotensive activities of Levodopa.Approved
NifedipineNifedipine may increase the orthostatic hypotensive activities of Levodopa.Approved
NilotinibThe metabolism of Levodopa can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the orthostatic hypotensive activities of Levodopa.Approved
NimodipineNimodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
NisoldipineNisoldipine may increase the orthostatic hypotensive activities of Levodopa.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levodopa.Approved
NitrendipineNitrendipine may increase the orthostatic hypotensive activities of Levodopa.Approved
Nitric OxideNitric Oxide may increase the orthostatic hypotensive activities of Levodopa.Approved
NitroglycerinNitroglycerin may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
NitroprussideNitroprusside may increase the orthostatic hypotensive activities of Levodopa.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levodopa.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Levodopa.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levodopa.Approved
ObinutuzumabObinutuzumab may increase the orthostatic hypotensive activities of Levodopa.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Levodopa is combined with Octamoxin.Withdrawn
OlanzapineThe therapeutic efficacy of Levodopa can be decreased when used in combination with Olanzapine.Approved, Investigational
OlmesartanOlmesartan may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levodopa.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levodopa.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Levodopa.Approved, Illicit
OrphenadrineLevodopa may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Levodopa.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levodopa.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Levodopa is combined with Oxetacaine.Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Levodopa.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levodopa.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levodopa.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levodopa.Approved, Investigational, Vet Approved
PaclitaxelPaclitaxel may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
PaliperidoneThe therapeutic efficacy of Levodopa can be decreased when used in combination with Paliperidone.Approved
PanobinostatThe serum concentration of Levodopa can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverinePapaverine may increase the hypotensive activities of Levodopa.Approved
ParaldehydeLevodopa may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Levodopa is combined with Pargyline.Approved
ParoxetineThe metabolism of Levodopa can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Levodopa can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levodopa.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levodopa.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
PerazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Perazine.Investigational
PerindoprilPerindopril may increase the orthostatic hypotensive activities of Levodopa.Approved
PerospironeThe therapeutic efficacy of Levodopa can be decreased when used in combination with Perospirone.Approved
PerphenazineThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Levodopa.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levodopa.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Levodopa is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levodopa.Approved
PhenoxybenzaminePhenoxybenzamine may increase the orthostatic hypotensive activities of Levodopa.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Levodopa.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Phenoxypropazine.Withdrawn
PhentolaminePhentolamine may increase the orthostatic hypotensive activities of Levodopa.Approved
PhenytoinThe therapeutic efficacy of Levodopa can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PimavanserinThe therapeutic efficacy of Levodopa can be decreased when used in combination with Pimavanserin.Investigational
PimozideThe therapeutic efficacy of Pimozide can be decreased when used in combination with Levodopa.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Levodopa.Approved
PipamperonePipamperone may increase the orthostatic hypotensive activities of Levodopa.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Levodopa is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Levodopa is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Levodopa is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Levodopa is combined with Pomalidomide.Approved
PramipexoleLevodopa may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levodopa.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Levodopa.Approved, Illicit
PrazosinPrazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levodopa.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Levodopa is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levodopa.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Levodopa.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levodopa.Approved, Investigational, Vet Approved
ProchlorperazineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Levodopa.Approved, Vet Approved
PromazineThe therapeutic efficacy of Promazine can be decreased when used in combination with Levodopa.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levodopa.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levodopa.Approved, Vet Approved
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Levodopa.Approved
PropofolPropofol may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Levodopa.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levodopa.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Levodopa.Investigational
PyridoxineThe therapeutic efficacy of Levodopa can be decreased when used in combination with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levodopa.Approved, Illicit
QuetiapineQuetiapine may increase the orthostatic hypotensive activities of Levodopa.Approved
QuinaprilQuinapril may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
QuinidineThe metabolism of Levodopa can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Levodopa can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Levodopa is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levodopa.Approved, Investigational
RamiprilRamipril may increase the orthostatic hypotensive activities of Levodopa.Approved
RanolazineThe metabolism of Levodopa can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Levodopa is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the orthostatic hypotensive activities of Levodopa.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levodopa.Approved, Withdrawn
ReserpineReserpine may increase the orthostatic hypotensive activities of Levodopa.Approved
RiociguatRiociguat may increase the orthostatic hypotensive activities of Levodopa.Approved
RisperidoneLevodopa may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Levodopa is combined with Ritanserin.Investigational
RitonavirThe metabolism of Levodopa can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Levodopa can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Levodopa.Vet Approved
RopiniroleLevodopa may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the orthostatic hypotensive activities of Levodopa.Approved
RotigotineLevodopa may increase the sedative activities of Rotigotine.Approved
RP5063The therapeutic efficacy of Levodopa can be decreased when used in combination with RP5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levodopa.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levodopa.Experimental
SacubitrilSacubitril may increase the orthostatic hypotensive activities of Levodopa.Approved
SafrazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Levodopa is combined with Sage 547.Investigational
SapropterinThe risk or severity of adverse effects can be increased when Sapropterin is combined with Levodopa.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levodopa.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levodopa.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Levodopa is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe therapeutic efficacy of Levodopa can be decreased when used in combination with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Levodopa can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
Sodium NitriteSodium Nitrite may increase the orthostatic hypotensive activities of Levodopa.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
SotalolSotalol may increase the orthostatic hypotensive activities of Levodopa.Approved
SpironolactoneSpironolactone may increase the orthostatic hypotensive activities of Levodopa.Approved
StiripentolThe metabolism of Levodopa can be decreased when combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the orthostatic hypotensive activities of Levodopa.Approved
SufentanilSufentanil may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Levodopa.Approved
SuvorexantLevodopa may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinTamsulosin may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Levodopa is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Levodopa is combined with Tasimelteon.Approved
TelmisartanTelmisartan may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levodopa.Approved
TerazosinTerazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
TerbinafineThe metabolism of Levodopa can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Levodopa is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levodopa.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levodopa.Investigational
ThalidomideLevodopa may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levodopa.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levodopa.Approved, Vet Approved
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Levodopa.Approved
ThioridazineThioridazine may increase the orthostatic hypotensive activities of Levodopa.Approved
ThiothixeneThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Levodopa.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levodopa.Approved
TiaprideThe risk or severity of adverse effects can be increased when Levodopa is combined with Tiapride.Investigational
TiclopidineThe metabolism of Levodopa can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Levodopa.Vet Approved
TimololTimolol may increase the orthostatic hypotensive activities of Levodopa.Approved
TipranavirThe metabolism of Levodopa can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the orthostatic hypotensive activities of Levodopa.Approved
TolazolineTolazoline may increase the orthostatic hypotensive activities of Levodopa.Approved, Vet Approved
TolcaponeTolcapone may increase the orthostatic hypotensive activities of Levodopa.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Levodopa is combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Levodopa.Approved
TorasemideTorasemide may increase the orthostatic hypotensive activities of Levodopa.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levodopa.Approved, Investigational
TrandolaprilTrandolapril may increase the orthostatic hypotensive activities of Levodopa.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Levodopa is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Levodopa is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Levodopa.Approved, Investigational
TretinoinTretinoin may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the orthostatic hypotensive activities of Levodopa.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levodopa.Approved
TrifluoperazineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Levodopa.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levodopa.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levodopa.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levodopa.Approved
Uc1010The risk or severity of adverse effects can be increased when Levodopa is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levodopa.Approved, Investigational
ValsartanValsartan may increase the orthostatic hypotensive activities of Levodopa.Approved, Investigational
VenlafaxineThe metabolism of Levodopa can be decreased when combined with Venlafaxine.Approved
VerapamilVerapamil may increase the orthostatic hypotensive activities of Levodopa.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Levodopa.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levodopa.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Levodopa.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levodopa.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Levodopa is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Levodopa is combined with Zimelidine.Withdrawn
ZiprasidoneThe therapeutic efficacy of Levodopa can be decreased when used in combination with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Levodopa.Vet Approved
ZolpidemLevodopa may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levodopa.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levodopa.Approved
ZotepineThe therapeutic efficacy of Levodopa can be decreased when used in combination with Zotepine.Approved
ZuclopenthixolThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Levodopa.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Vincenzo Cannata, Giancarlo Tamerlani, Mauro Morotti, “Process for the synthesis of the levodopa.” U.S. Patent US4962223, issued December, 1986.

US4962223
General References
  1. Pinho MJ, Serrao MP, Gomes P, Hopfer U, Jose PA, Soares-da-Silva P: Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney Int. 2004 Jul;66(1):216-26. [PubMed:15200428 ]
  2. Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S: The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 2000 Oct 6;879(1-2):115-21. [PubMed:11011012 ]
External Links
ATC CodesN04BA03N04BA02N04BA01
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (37.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8715
Blood Brain Barrier-0.9264
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5734
P-glycoprotein inhibitor INon-inhibitor0.989
P-glycoprotein inhibitor IINon-inhibitor0.988
Renal organic cation transporterNon-inhibitor0.9211
CYP450 2C9 substrateNon-substrate0.8236
CYP450 2D6 substrateNon-substrate0.8514
CYP450 3A4 substrateNon-substrate0.7117
CYP450 1A2 substrateNon-inhibitor0.9467
CYP450 2C9 inhibitorNon-inhibitor0.9765
CYP450 2D6 inhibitorNon-inhibitor0.9576
CYP450 2C19 inhibitorNon-inhibitor0.9504
CYP450 3A4 inhibitorNon-inhibitor0.914
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9713
Ames testAMES toxic0.9106
CarcinogenicityNon-carcinogens0.941
BiodegradationReady biodegradable0.7332
Rat acute toxicity2.0131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9872
hERG inhibition (predictor II)Non-inhibitor0.9524
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg/1
Tablet, film coatedOral
GelEnteral
SuspensionEnteral
Tablet, orally disintegratingOral
CapsuleOral
Capsule, extended releaseOral
TabletOral
Tablet, extended releaseOral
Prices
Unit descriptionCostUnit
L-dopa powder15.19USD g
Levodopa powder7.31USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6500867 No2000-06-292020-06-29Us
US6797732 No2000-06-292020-06-29Us
US7094427 No2002-05-292022-05-29Us
US8377474 No2008-12-262028-12-26Us
US8454998 No2008-12-262028-12-26Us
US8557283 No2008-12-262028-12-26Us
US9089607 No2008-12-262028-12-26Us
US9089608 No2008-12-262028-12-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point284-285U.S. Patent 3,253,023.
water solubility5000 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-2.39SANGSTER (1993)
logS-1.6ADME Research, USCD
pKa2.32 (at 25 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility3.3 mg/mLALOGPS
logP-2.3ALOGPS
logP-1.8ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)1.65ChemAxon
pKa (Strongest Basic)9.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area103.78 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity49.08 m3·mol-1ChemAxon
Polarizability18.91 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.19 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-014i-0790000000-b2f7f063a2c8197c7eddView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-014i-0690000000-622497b3104c6082a45dView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-00xr-9350000000-b0cc4636931d2de64d81View in MoNA
GC-MSGC-MS Spectrum - GC-MS (4 TMS)splash10-014i-0590000000-4474e81e4226bb4e1d4cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-0uea-0900000000-8eb71aa0cc8622f097a2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0a59-2900000000-bf63b9b719959b82b543View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-056r-9300000000-a78b0b31dd33fe8479a7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-0f6t-0911000000-15affa616923dfb9c45aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-000i-0900000000-22d8267801d0eb0b73c2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-001i-0900000000-2c310034a1a871502b4cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-0udi-0900000000-5e6020c952f741531fcbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-0007-0970100000-49594dae82ce73e734e6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-001i-0900000000-2183a68f58b951f3f1c7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-03di-0900000000-0030db588fbd92c5b761View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-0006-0090000000-544615463a975baae9e4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0002-0729111000-0a20b01f58fff8ad7ef0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-004i-0900000000-c8095a31ed4b3dbbc646View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-03di-0190000000-41515cba3a6929721859View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0002-0900000000-8074c509ef5bae1129fcView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0006-0502193020-497bfad7ba247159ca00View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-004i-0900000000-0b0d4b6dcb7f1fa24e1aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-004i-0029800000-05f40324c8c1fec7963aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0006-0000090000-c0cd80185ce47b30e5feView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-0002-0900000000-df116b84981cf4a1371aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, Positivesplash10-0f6t-0900000000-1c1c39a8880442ea18dfView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentCatecholamines and derivatives
Alternative Parents
Substituents
  • 3-phenylpropanoic-acid
  • Catecholamine
  • L-alpha-amino acid
  • Amphetamine or derivatives
  • Alpha-amino acid or derivatives
  • Alpha-amino acid
  • Aralkylamine
  • Amino fatty acid
  • Fatty acyl
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 . [PubMed:18549347 ]
  2. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  3. Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. [PubMed:9633680 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 . [PubMed:18549347 ]
  2. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  3. Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. [PubMed:9633680 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Dupre KB, Eskow KL, Negron G, Bishop C: The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 2007 Jul 16;1158:135-43. Epub 2007 May 8. [PubMed:17553470 ]
  2. Mori A, Ohashi S, Nakai M, Moriizumi T, Mitsumoto Y: Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res. 2005 Mar;51(3):265-74. Epub 2005 Jan 8. [PubMed:15710490 ]
  3. Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Ciro-Candiano IC, Gambardella A, Quattrone A: Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005 Apr;62(4):601-5. [PubMed:15824260 ]
  4. Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, Axelrod JD, Cheyette BN, Simon MI, Lester HA, Schwarz J: D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci. 2005 Feb 23;25(8):2157-65. [PubMed:15728856 ]
  5. Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 . [PubMed:18549347 ]
  6. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  7. Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. [PubMed:9633680 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 . [PubMed:18549347 ]
  2. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  3. Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. [PubMed:9633680 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 . [PubMed:18549347 ]
  2. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  3. Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. [PubMed:9633680 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Pyridoxal phosphate binding
Specific Function:
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
Gene Name:
DDC
Uniprot ID:
P20711
Molecular Weight:
53925.815 Da
References
  1. BIRKMAYER W, HORNYKIEWICZ O: [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961 Nov 10;73:787-8. [PubMed:13869404 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50. [PubMed:10052994 ]
  2. Tamai I, Nakanishi T, Nakahara H, Sai Y, Ganapathy V, Leibach FH, Tsuji A: Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. J Pharm Sci. 1998 Dec;87(12):1542-6. [PubMed:10189264 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
Gene Name:
SLC16A10
Uniprot ID:
Q8TF71
Molecular Weight:
55492.07 Da
References
  1. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. [PubMed:11278508 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Peptide antigen binding
Specific Function:
Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Involved in cellular amino acid uptake. Acts as an amino acid exchanger. Involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the ...
Gene Name:
SLC7A5
Uniprot ID:
Q01650
Molecular Weight:
55009.62 Da
References
  1. Pinho MJ, Serrao MP, Gomes P, Hopfer U, Jose PA, Soares-da-Silva P: Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney Int. 2004 Jul;66(1):216-26. [PubMed:15200428 ]
  2. Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S: The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 2000 Oct 6;879(1-2):115-21. [PubMed:11011012 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxin transporter activity
Specific Function:
Sodium-independent, high-affinity transport of small and large neutral amino acids such as alanine, serine, threonine, cysteine, phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Acts as an amino acid exchanger. Has higher affinity for L-phenylalanine than LAT1 but lower affinity for glutamine and serine. L-alanine is transported at physiological conc...
Gene Name:
SLC7A8
Uniprot ID:
Q9UHI5
Molecular Weight:
58381.12 Da
References
  1. Pinho MJ, Serrao MP, Gomes P, Hopfer U, Jose PA, Soares-da-Silva P: Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney Int. 2004 Jul;66(1):216-26. [PubMed:15200428 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:45